Enhertu Preferred Second-Line Therapy for HER2-Positive Breast Cancer

Trastuzumab deruxtecan (T-DXd), marketed as Enhertu, has been established as the preferred second-line therapy for patients with HER2-positive metastatic breast cancer. This designation is based on the outcomes of the pivotal DESTINY-Breast03 trial, which demonstrated significant clinical benefits for the drug in this patient population. The trial's findings support its use regardless of the hormone receptor status of the tumor, broadening its applicability.

The DESTINY-Breast03 trial compared Enhertu to trastuzumab emtansine (Kadcyla) in patients who had previously received trastuzumab and a taxane. The study revealed a substantial improvement in progression-free survival (PFS) for patients treated with Enhertu. Specifically, the median PFS was 28.4 months for the Enhertu arm compared to 6.8 months for the trastuzumab emtansine arm, representing a 72% reduction in the risk of disease progression or death. Overall survival (OS) also showed a positive trend, with a median OS of 23.4 months in the Enhertu group versus 17.7 months in the comparator group.

These results have led to updated treatment guidelines, positioning Enhertu as a crucial option after initial therapies for HER2-positive metastatic breast cancer. The drug's mechanism of action involves delivering a potent cytotoxic agent directly to cancer cells that overexpress HER2, thereby minimizing systemic toxicity. The trial's robust data package has been instrumental in its widespread adoption and recommendation by major oncology societies.

Further analysis of the DESTINY-Breast03 trial data has also provided insights into the safety profile of Enhertu. While the drug is associated with certain side effects, including interstitial lung disease and myelosuppression, these were generally manageable and consistent with previous observations. The benefit-risk profile, as demonstrated by the trial's efficacy endpoints, strongly favors Enhertu in the second-line setting for HER2-positive metastatic breast cancer.